With the recent breakthroughs in both PI3K inhibitor alpelisib and immune checkpoint blockade (ICB) treatment in breast cancer, the potential for PI3K inhibition in combination with PD-1/PD-L1 blockade merits evaluation. The gene discussed is CD274; the disease is breast carcinoma.